|
ZNF160 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.25100000031497E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.50830000000113E-05 |
| Normal-vs-Stage2 |
1.87251000000055E-05 |
| Normal-vs-Stage3 |
3.83739999998411E-07 |
| Normal-vs-Stage4 |
2.15510000001196E-06 |
| Stage1-vs-Stage2 |
1.676200E-01 |
| Stage1-vs-Stage3 |
7.526300E-02 |
| Stage1-vs-Stage4 |
1.407830E-01 |
| Stage2-vs-Stage3 |
9.498800E-01 |
| Stage2-vs-Stage4 |
9.729000E-01 |
| Stage3-vs-Stage4 |
9.170000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.17759999998623E-06 |
| Normal-vs-AfricanAmerican |
1.786120E-02 |
| Normal-vs-Asian |
8.012100E-04 |
| Caucasian-vs-AfricanAmerican |
5.589800E-01 |
| Caucasian-vs-Asian |
5.119800E-01 |
| AfricanAmerican-vs-Asian |
8.563200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.5942000000011E-05 |
| Normal-vs-Female |
4.00140000023086E-07 |
| Male-vs-Female |
3.702000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.361350E-04 |
| Normal-vs-Age(41-60Yrs) |
1.65090999999506E-05 |
| Normal-vs-Age(61-80Yrs) |
2.13699999918049E-08 |
| Normal-vs-Age(81-100Yrs) |
7.337900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.057800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.764200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.466800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.085030E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.133800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.336600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.858190E-03 |
| Classical-VS-Follicular |
7.262500E-03 |
| Classical-VS-Other |
4.901600E-01 |
| Classical-VS-Normal |
6.22799999999701E-05 |
| Tall-VS-Follicular |
6.984600E-01 |
| Tall-VS-Other |
5.093000E-01 |
| Tall-VS-Normal |
2.62459999955666E-07 |
| Follicular-VS-Other |
7.536600E-01 |
| Follicular-VS-Normal |
1.96019999998409E-06 |
| Other-VS-Normal |
4.450500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.89029999986268E-07 |
| Normal-vs-N1 |
6.785200E-04 |
| N0-vs-N1 |
4.694000E-01 |
|
|
